Watch the Dallas Symposium LIVE, and fundraiser auction
Ticket proceeds support mindat.org! - click here...
Log InRegister
Quick Links : The Mindat ManualThe Rock H. Currier Digital LibraryMindat Newsletter [Free Download]
Home PageAbout MindatThe Mindat ManualHistory of MindatCopyright StatusWho We AreContact UsAdvertise on Mindat
Donate to MindatCorporate SponsorshipSponsor a PageSponsored PagesMindat AdvertisersAdvertise on Mindat
Learning CenterWhat is a mineral?The most common minerals on earthInformation for EducatorsMindat ArticlesThe ElementsThe Rock H. Currier Digital LibraryGeologic Time
Minerals by PropertiesMinerals by ChemistryAdvanced Locality SearchRandom MineralRandom LocalitySearch by minIDLocalities Near MeSearch ArticlesSearch GlossaryMore Search Options
Search For:
Mineral Name:
Locality Name:
Keyword(s):
 
The Mindat ManualAdd a New PhotoRate PhotosLocality Edit ReportCoordinate Completion ReportAdd Glossary Item
Mining CompaniesStatisticsUsersMineral MuseumsClubs & OrganizationsMineral Shows & EventsThe Mindat DirectoryDevice SettingsThe Mineral Quiz
Photo SearchPhoto GalleriesSearch by ColorNew Photos TodayNew Photos YesterdayMembers' Photo GalleriesPast Photo of the Day GalleryPhotography

(2018, September) Reactions Weekly Vol. 1721 (1) Springer Science and Business Media LLC

Advanced
   -   Only viewable:
Reference TypeJournal (issue)
JournalReactions Weekly
Year2018 (September)Volume1721
Issue1
PublisherSpringer Science and Business Media LLC
Mindat Ref. ID13373524Long-form Identifiermindat:1:5:13373524:8
GUID0
Full Reference(2018, September) Reactions Weekly Vol. 1721 (1) Springer Science and Business Media LLC
Plain Text(2018, September) Reactions Weekly Vol. 1721 (1) Springer Science and Business Media LLC
In(2018) Reactions Weekly Vol. 1721. Springer Science and Business Media LLC

Contains

1 2
Page 1 of 2		Next Page
(2018) Atezolizumab linked with immune-related nephritis. Reactions Weekly, 1721 (1) 1 doi:10.1007/s40278-018-52038-3
(2018) Muscle-related complaints with alirocumab and evolocumab. Reactions Weekly, 1721 (1) 2 doi:10.1007/s40278-018-52039-3
(2018) Regulatory updates following recall of valsartan medicines. Reactions Weekly, 1721 (1) 3 doi:10.1007/s40278-018-52040-2
(2018) Acute respiratory illness with statins and flu vaccine. Reactions Weekly, 1721 (1) 4 doi:10.1007/s40278-018-52041-2
(2018) Adverse effects of aspirin in healthy elderly. Reactions Weekly, 1721 (1) 5 doi:10.1007/s40278-018-52042-2
(2018) Childhood leukaemia following hormonal contraception exposure. Reactions Weekly, 1721 (1) 6 doi:10.1007/s40278-018-52043-2
(2018) Idarucizumab reverses haemorrhagic effects of dabigatran. Reactions Weekly, 1721 (1) 7 doi:10.1007/s40278-018-52044-2
(2018) Immune checkpoint inhibitors: fatal toxic effects. Reactions Weekly, 1721 (1) 8 doi:10.1007/s40278-018-52045-2
(2018) Methotrexate: neurotoxicity in paediatric ALL. Reactions Weekly, 1721 (1) 9 doi:10.1007/s40278-018-52046-2
(2018) News from 34th ICPE. Reactions Weekly, 1721 (1) 10-11 doi:10.1007/s40278-018-52047-2
(2018) SpA-associated ethesitis/osteitis with vedolizumab. Reactions Weekly, 1721 (1) 11 doi:10.1007/s40278-018-52048-2
(2018) Acetazolamide/topiramate. Reactions Weekly, 1721 (1) 12 doi:10.1007/s40278-018-52049-2
(2018) Aciclovir. Reactions Weekly, 1721 (1) 13 doi:10.1007/s40278-018-52050-1
(2018) Adalimumab. Reactions Weekly, 1721 (1) 14 doi:10.1007/s40278-018-52051-1
(2018) Adalimumab. Reactions Weekly, 1721 (1) 15 doi:10.1007/s40278-018-52052-1
(2018) Adalimumab. Reactions Weekly, 1721 (1) 16 doi:10.1007/s40278-018-52053-1
(2018) Afatinib/poziotinib. Reactions Weekly, 1721 (1) 17 doi:10.1007/s40278-018-52054-1
(2018) Alemtuzumab. Reactions Weekly, 1721 (1) 18 doi:10.1007/s40278-018-52055-1
(2018) Alteplase. Reactions Weekly, 1721 (1) 19 doi:10.1007/s40278-018-52056-1
(2018) Alteplase. Reactions Weekly, 1721 (1) 20 doi:10.1007/s40278-018-52057-1
(2018) Amiodarone. Reactions Weekly, 1721 (1) 21 doi:10.1007/s40278-018-52058-1
(2018) Amiodarone. Reactions Weekly, 1721 (1) 22 doi:10.1007/s40278-018-52059-1
(2018) Amiodarone. Reactions Weekly, 1721 (1) 23 doi:10.1007/s40278-018-52060-0
(2018) Amiodarone. Reactions Weekly, 1721 (1) 24 doi:10.1007/s40278-018-52061-0
(2018) Amoxicillin. Reactions Weekly, 1721 (1) 25 doi:10.1007/s40278-018-52062-0
(2018) Amoxicillin/clavulanic acid. Reactions Weekly, 1721 (1) 26 doi:10.1007/s40278-018-52063-0
(2018) Amphotericin-B-liposomal/fluconazole/itraconazole. Reactions Weekly, 1721 (1) 27 doi:10.1007/s40278-018-52064-0
(2018) Antibacterials. Reactions Weekly, 1721 (1) 28 doi:10.1007/s40278-018-52065-0
(2018) Antineoplastics. Reactions Weekly, 1721 (1) 29 doi:10.1007/s40278-018-52066-0
(2018) Antineoplastics. Reactions Weekly, 1721 (1) 30 doi:10.1007/s40278-018-52067-0
(2018) Antineoplastics. Reactions Weekly, 1721 (1) 31 doi:10.1007/s40278-018-52068-0
(2018) Antineoplastics. Reactions Weekly, 1721 (1) 32 doi:10.1007/s40278-018-52069-0
(2018) Antineoplastics. Reactions Weekly, 1721 (1) 33 doi:10.1007/s40278-018-52070-z
(2018) Antineoplastics. Reactions Weekly, 1721 (1) 34 doi:10.1007/s40278-018-52071-z
(2018) Antipsoriatics. Reactions Weekly, 1721 (1) 35 doi:10.1007/s40278-018-52072-z
(2018) Antiretrovirals. Reactions Weekly, 1721 (1) 36 doi:10.1007/s40278-018-52073-z
(2018) Antirheumatics/hydroxychloroquine/thalidomide. Reactions Weekly, 1721 (1) 37 doi:10.1007/s40278-018-52074-z
(2018) Antituberculars. Reactions Weekly, 1721 (1) 38 doi:10.1007/s40278-018-52075-z
(2018) Antituberculars/moxifloxacin. Reactions Weekly, 1721 (1) 39 doi:10.1007/s40278-018-52076-z
(2018) Antivirals. Reactions Weekly, 1721 (1) 40 doi:10.1007/s40278-018-52077-z
(2018) Apixaban/aspirin/clopidogrel. Reactions Weekly, 1721 (1) 41 doi:10.1007/s40278-018-52078-z
(2018) Apixaban/phenprocoumon. Reactions Weekly, 1721 (1) 42 doi:10.1007/s40278-018-52079-z
(2018) Apixaban/phenprocoumon/rivaroxaban. Reactions Weekly, 1721 (1) 43 doi:10.1007/s40278-018-52080-y
(2018) Apomorphine/levodopa. Reactions Weekly, 1721 (1) 44 doi:10.1007/s40278-018-52081-y
(2018) Ascorbic acid. Reactions Weekly, 1721 (1) 45 doi:10.1007/s40278-018-52082-y
(2018) Ascorbic acid. Reactions Weekly, 1721 (1) 46 doi:10.1007/s40278-018-52083-y
(2018) Aspirin. Reactions Weekly, 1721 (1) 47 doi:10.1007/s40278-018-52084-y
(2018) Aspirin. Reactions Weekly, 1721 (1) 48 doi:10.1007/s40278-018-52085-y
(2018) Aspirin/clopidogrel/dasatinib. Reactions Weekly, 1721 (1) 49 doi:10.1007/s40278-018-52086-y
(2018) Aspirin/morphine/vinegar interaction. Reactions Weekly, 1721 (1) 50 doi:10.1007/s40278-018-52087-y
(2018) Atorvastatin. Reactions Weekly, 1721 (1) 51 doi:10.1007/s40278-018-52088-y
(2018) Atorvastatin/simvastatin. Reactions Weekly, 1721 (1) 52 doi:10.1007/s40278-018-52089-y
(2018) Atorvastatin/simvastatin. Reactions Weekly, 1721 (1) 53 doi:10.1007/s40278-018-52090-x
(2018) Azacitidine. Reactions Weekly, 1721 (1) 54 doi:10.1007/s40278-018-52091-x
(2018) Azathioprine. Reactions Weekly, 1721 (1) 55 doi:10.1007/s40278-018-52092-x
(2018) Azathioprine/budesonide/infliximab. Reactions Weekly, 1721 (1) 56 doi:10.1007/s40278-018-52093-x
(2018) Azathioprine/corticosteroids. Reactions Weekly, 1721 (1) 57 doi:10.1007/s40278-018-52094-x
(2018) Azathioprine/dexamethasone/tacrolimus. Reactions Weekly, 1721 (1) 58 doi:10.1007/s40278-018-52095-x
(2018) Azathioprine/infliximab/mesalazine. Reactions Weekly, 1721 (1) 59 doi:10.1007/s40278-018-52096-x
(2018) Azathioprine/prednisone/rituximab. Reactions Weekly, 1721 (1) 60 doi:10.1007/s40278-018-52097-x
(2018) Bevacizumab. Reactions Weekly, 1721 (1) 61 doi:10.1007/s40278-018-52098-x
(2018) Bevacizumab/irinotecan/polyethylene glycol. Reactions Weekly, 1721 (1) 62 doi:10.1007/s40278-018-52099-x
(2018) Buprenorphine. Reactions Weekly, 1721 (1) 63 doi:10.1007/s40278-018-52100-4
(2018) Buprenorphine/naloxone. Reactions Weekly, 1721 (1) 64 doi:10.1007/s40278-018-52101-4
(2018) Calcium carbonate/colecalciferol. Reactions Weekly, 1721 (1) 65 doi:10.1007/s40278-018-52102-4
(2018) Candesartan cilexetil. Reactions Weekly, 1721 (1) 66 doi:10.1007/s40278-018-52103-4
(2018) Carbamazepine. Reactions Weekly, 1721 (1) 67 doi:10.1007/s40278-018-52104-4
(2018) Carbamazepine. Reactions Weekly, 1721 (1) 68 doi:10.1007/s40278-018-52105-4
(2018) Carbamazepine. Reactions Weekly, 1721 (1) 69 doi:10.1007/s40278-018-52106-4
(2018) Carboplatin/paclitaxel. Reactions Weekly, 1721 (1) 70 doi:10.1007/s40278-018-52107-4
(2018) Cefoxitin/meropenem. Reactions Weekly, 1721 (1) 71 doi:10.1007/s40278-018-52108-4
(2018) Ceftolozane/tazobactam. Reactions Weekly, 1721 (1) 72 doi:10.1007/s40278-018-52109-4
(2018) Ceftriaxone. Reactions Weekly, 1721 (1) 73 doi:10.1007/s40278-018-52110-3
(2018) Ceftriaxone/ciprofloxacin. Reactions Weekly, 1721 (1) 74 doi:10.1007/s40278-018-52111-3
(2018) Ceritinib. Reactions Weekly, 1721 (1) 75 doi:10.1007/s40278-018-52112-3
(2018) Certolizumab pegol/etanercept/tocilizumab. Reactions Weekly, 1721 (1) 76 doi:10.1007/s40278-018-52113-3
(2018) Cetuximab. Reactions Weekly, 1721 (1) 77 doi:10.1007/s40278-018-52114-3
(2018) Chlormethine/prednisolone. Reactions Weekly, 1721 (1) 78 doi:10.1007/s40278-018-52115-3
(2018) Ciclosporin/leflunomide/mycophenolate/tacrolimus. Reactions Weekly, 1721 (1) 79 doi:10.1007/s40278-018-52116-3
(2018) Ciclosporin/prednisone. Reactions Weekly, 1721 (1) 80 doi:10.1007/s40278-018-52117-3
(2018) Cinacalcet. Reactions Weekly, 1721 (1) 81 doi:10.1007/s40278-018-52118-3
(2018) Cisplatin/cyclophosphamide/treosulfan. Reactions Weekly, 1721 (1) 82 doi:10.1007/s40278-018-52119-3
(2018) Cisplatin/docetaxel/osimertinib. Reactions Weekly, 1721 (1) 83 doi:10.1007/s40278-018-52120-2
(2018) Cisplatin/gemcitabine. Reactions Weekly, 1721 (1) 84 doi:10.1007/s40278-018-52121-2
(2018) Cisplatin/gimeracil/oteracil/tegafur. Reactions Weekly, 1721 (1) 85 doi:10.1007/s40278-018-52122-2
(2018) Cladribine/cytarabine/unspecified granulocyte-colony-stimulating factors. Reactions Weekly, 1721 (1) 86 doi:10.1007/s40278-018-52123-2
(2018) Clarithromycin/hydroxyzine. Reactions Weekly, 1721 (1) 87 doi:10.1007/s40278-018-52124-2
(2018) Clonazepam/beer interaction. Reactions Weekly, 1721 (1) 88 doi:10.1007/s40278-018-52125-2
(2018) Colchicine overdose. Reactions Weekly, 1721 (1) 89 doi:10.1007/s40278-018-52126-2
(2018) Colchicine overdose. Reactions Weekly, 1721 (1) 90 doi:10.1007/s40278-018-52127-2
(2018) Colchicine/dapsone. Reactions Weekly, 1721 (1) 91 doi:10.1007/s40278-018-52128-2
(2018) Colistin. Reactions Weekly, 1721 (1) 92 doi:10.1007/s40278-018-52129-2
(2018) Correction to: Dimethyl fumarate. Reactions Weekly, 1721 (1) 93 doi:10.1007/s40278-018-52130-1
(2018) Cotrimoxazole. Reactions Weekly, 1721 (1) 94 doi:10.1007/s40278-018-52131-1
(2018) Cotrimoxazole/prednisolone. Reactions Weekly, 1721 (1) 95 doi:10.1007/s40278-018-52132-1
(2018) Crizotinib/erlotinib/osimertinib. Reactions Weekly, 1721 (1) 96 doi:10.1007/s40278-018-52133-1
(2018) Cyclophosphamide. Reactions Weekly, 1721 (1) 97 doi:10.1007/s40278-018-52134-1
(2018) Cyclophosphamide. Reactions Weekly, 1721 (1) 98 doi:10.1007/s40278-018-52135-1
(2018) Cyclophosphamide/mycophenolate-mofetil/rituximab. Reactions Weekly, 1721 (1) 99 doi:10.1007/s40278-018-52136-1
(2018) Cyclophosphamide/prednisolone. Reactions Weekly, 1721 (1) 100 doi:10.1007/s40278-018-52137-1
(2018) Dabigatran etexilate. Reactions Weekly, 1721 (1) 101 doi:10.1007/s40278-018-52138-1
(2018) Dalteparin sodium/treprostinil. Reactions Weekly, 1721 (1) 102 doi:10.1007/s40278-018-52139-1
(2018) Dapsone. Reactions Weekly, 1721 (1) 103 doi:10.1007/s40278-018-52140-0
(2018) Dapsone. Reactions Weekly, 1721 (1) 104 doi:10.1007/s40278-018-52141-0
(2018) Decitabine. Reactions Weekly, 1721 (1) 105 doi:10.1007/s40278-018-52142-0
(2018) Desflurane. Reactions Weekly, 1721 (1) 106 doi:10.1007/s40278-018-52143-0
(2018) Dexamethasone. Reactions Weekly, 1721 (1) 107 doi:10.1007/s40278-018-52144-0
(2018) Diclofenac. Reactions Weekly, 1721 (1) 108 doi:10.1007/s40278-018-52145-0
(2018) Diltiazem. Reactions Weekly, 1721 (1) 109 doi:10.1007/s40278-018-52146-0
(2018) Dipyrone. Reactions Weekly, 1721 (1) 110 doi:10.1007/s40278-018-52147-0
(2018) Disulfiram. Reactions Weekly, 1721 (1) 111 doi:10.1007/s40278-018-52148-0
(2018) Docetaxel/pertuzumab/trastuzumab. Reactions Weekly, 1721 (1) 112 doi:10.1007/s40278-018-52149-0
(2018) Doxorubicin. Reactions Weekly, 1721 (1) 113 doi:10.1007/s40278-018-52150-z
(2018) Doxycycline/prednisone/rituximab. Reactions Weekly, 1721 (1) 114 doi:10.1007/s40278-018-52151-z
(2018) Droperidol/haloperidol. Reactions Weekly, 1721 (1) 115 doi:10.1007/s40278-018-52152-z
(2018) DTaP vaccine/neomycin/pneumococcal vaccine. Reactions Weekly, 1721 (1) 116 doi:10.1007/s40278-018-52153-z
(2018) Eculizumab/steroids. Reactions Weekly, 1721 (1) 117 doi:10.1007/s40278-018-52154-z
(2018) Enbucrilate/sirolimus/sodium tetradecyl sulfate. Reactions Weekly, 1721 (1) 118 doi:10.1007/s40278-018-52155-z
(2018) Enoxaparin sodium/vancomycin. Reactions Weekly, 1721 (1) 119 doi:10.1007/s40278-018-52156-z
(2018) Entecavir. Reactions Weekly, 1721 (1) 120 doi:10.1007/s40278-018-52157-z
(2018) Epinephrine. Reactions Weekly, 1721 (1) 121 doi:10.1007/s40278-018-52158-z
(2018) Epinephrine/flecainide. Reactions Weekly, 1721 (1) 122 doi:10.1007/s40278-018-52159-z
(2018) Epinephrine/lidocaine/ropivacaine. Reactions Weekly, 1721 (1) 123 doi:10.1007/s40278-018-52160-y
(2018) Eribulin. Reactions Weekly, 1721 (1) 124 doi:10.1007/s40278-018-52161-y
(2018) Erythromycin/simvastatin. Reactions Weekly, 1721 (1) 125 doi:10.1007/s40278-018-52162-y
(2018) Exenatide. Reactions Weekly, 1721 (1) 126 doi:10.1007/s40278-018-52163-y
(2018) Febuxostat. Reactions Weekly, 1721 (1) 127 doi:10.1007/s40278-018-52164-y
(2018) Fentanyl. Reactions Weekly, 1721 (1) 128 doi:10.1007/s40278-018-52165-y
(2018) Ferric-carboxymaltose. Reactions Weekly, 1721 (1) 129 doi:10.1007/s40278-018-52166-y
(2018) Fexofenadine/pseudoephedrine. Reactions Weekly, 1721 (1) 130 doi:10.1007/s40278-018-52167-y
(2018) Flucloxacillin/paracetamol interaction. Reactions Weekly, 1721 (1) 131 doi:10.1007/s40278-018-52168-y
(2018) Fluorouracil. Reactions Weekly, 1721 (1) 132 doi:10.1007/s40278-018-52169-y
(2018) Fluorouracil/irinotecan/oxaliplatin. Reactions Weekly, 1721 (1) 133 doi:10.1007/s40278-018-52170-x
(2018) Furosemide. Reactions Weekly, 1721 (1) 134 doi:10.1007/s40278-018-52171-x
(2018) Gemcitabine. Reactions Weekly, 1721 (1) 135 doi:10.1007/s40278-018-52172-x
(2018) Golimumab. Reactions Weekly, 1721 (1) 136 doi:10.1007/s40278-018-52173-x
(2018) Golimumab. Reactions Weekly, 1721 (1) 137 doi:10.1007/s40278-018-52174-x
(2018) Heparin. Reactions Weekly, 1721 (1) 138 doi:10.1007/s40278-018-52175-x
(2018) Heparin overdose. Reactions Weekly, 1721 (1) 139 doi:10.1007/s40278-018-52176-x
(2018) Heparin/rivaroxaban. Reactions Weekly, 1721 (1) 140 doi:10.1007/s40278-018-52177-x
(2018) Hib-dtap-poliovirus-vaccine/influenza-virus-vaccine/measles-mumps-and-rubella-virus-vaccine. Reactions Weekly, 1721 (1) 141 doi:10.1007/s40278-018-52178-x
(2018) Hydrogen peroxide overdose. Reactions Weekly, 1721 (1) 142 doi:10.1007/s40278-018-52179-x
(2018) Hydroxycarbamide. Reactions Weekly, 1721 (1) 143 doi:10.1007/s40278-018-52180-9
(2018) Hydroxychloroquine. Reactions Weekly, 1721 (1) 144 doi:10.1007/s40278-018-52181-9
(2018) Hydroxychloroquine. Reactions Weekly, 1721 (1) 145 doi:10.1007/s40278-018-52182-9
(2018) Hydroxychloroquine. Reactions Weekly, 1721 (1) 146 doi:10.1007/s40278-018-52183-9
(2018) Imiquimod. Reactions Weekly, 1721 (1) 147 doi:10.1007/s40278-018-52184-9
(2018) Immune-globulin. Reactions Weekly, 1721 (1) 148 doi:10.1007/s40278-018-52185-9
(2018) Immunosuppressants. Reactions Weekly, 1721 (1) 149 doi:10.1007/s40278-018-52186-9
(2018) Immunosuppressants. Reactions Weekly, 1721 (1) 150 doi:10.1007/s40278-018-52187-9
(2018) Immunosuppressants. Reactions Weekly, 1721 (1) 151 doi:10.1007/s40278-018-52188-9
(2018) Immunosuppressants. Reactions Weekly, 1721 (1) 152 doi:10.1007/s40278-018-52189-9
(2018) Immunosuppressants. Reactions Weekly, 1721 (1) 153 doi:10.1007/s40278-018-52190-8
(2018) Infliximab. Reactions Weekly, 1721 (1) 154 doi:10.1007/s40278-018-52191-8
(2018) Ingenol-mebutate. Reactions Weekly, 1721 (1) 155 doi:10.1007/s40278-018-52192-8
(2018) Insulin-glargine. Reactions Weekly, 1721 (1) 156 doi:10.1007/s40278-018-52193-8
(2018) Interferon. Reactions Weekly, 1721 (1) 157 doi:10.1007/s40278-018-52194-8
(2018) Interferon-α. Reactions Weekly, 1721 (1) 158 doi:10.1007/s40278-018-52195-8
(2018) Ipilimumab. Reactions Weekly, 1721 (1) 159 doi:10.1007/s40278-018-52196-8
(2018) Ipilimumab/nivolumab. Reactions Weekly, 1721 (1) 160 doi:10.1007/s40278-018-52197-8
(2018) Ipilimumab/nivolumab. Reactions Weekly, 1721 (1) 161 doi:10.1007/s40278-018-52198-8
(2018) Ipilimumab/nivolumab. Reactions Weekly, 1721 (1) 162 doi:10.1007/s40278-018-52199-8
(2018) Ipilimumab/pembrolizumab. Reactions Weekly, 1721 (1) 163 doi:10.1007/s40278-018-52200-2
(2018) Ixekizumab. Reactions Weekly, 1721 (1) 164 doi:10.1007/s40278-018-52201-2
(2018) Ixekizumab. Reactions Weekly, 1721 (1) 165 doi:10.1007/s40278-018-52202-2
(2018) Ledipasvir/sofosbuvir. Reactions Weekly, 1721 (1) 166 doi:10.1007/s40278-018-52203-2
(2018) Lenvatinib. Reactions Weekly, 1721 (1) 167 doi:10.1007/s40278-018-52204-2
(2018) Lenvatinib. Reactions Weekly, 1721 (1) 168 doi:10.1007/s40278-018-52205-2
(2018) Lenvatinib/sorafenib. Reactions Weekly, 1721 (1) 169 doi:10.1007/s40278-018-52206-2
(2018) Levamisole. Reactions Weekly, 1721 (1) 170 doi:10.1007/s40278-018-52207-2
(2018) Levobupivacaine. Reactions Weekly, 1721 (1) 171 doi:10.1007/s40278-018-52208-2
(2018) Levodopa. Reactions Weekly, 1721 (1) 172 doi:10.1007/s40278-018-52209-2
(2018) Lidocaine/epinephrine. Reactions Weekly, 1721 (1) 173 doi:10.1007/s40278-018-52210-1
(2018) Lidocaine/prilocaine. Reactions Weekly, 1721 (1) 174 doi:10.1007/s40278-018-52211-1
(2018) Linagliptin. Reactions Weekly, 1721 (1) 175 doi:10.1007/s40278-018-52212-1
(2018) Linezolid/moxifloxacin. Reactions Weekly, 1721 (1) 176 doi:10.1007/s40278-018-52213-1
(2018) Lithium. Reactions Weekly, 1721 (1) 177 doi:10.1007/s40278-018-52214-1
(2018) Lithium. Reactions Weekly, 1721 (1) 178 doi:10.1007/s40278-018-52215-1
(2018) Metformin overdose. Reactions Weekly, 1721 (1) 179 doi:10.1007/s40278-018-52216-1
(2018) Methotrexate. Reactions Weekly, 1721 (1) 180 doi:10.1007/s40278-018-52217-1
(2018) Methotrexate. Reactions Weekly, 1721 (1) 181 doi:10.1007/s40278-018-52218-1
(2018) Methotrexate. Reactions Weekly, 1721 (1) 182 doi:10.1007/s40278-018-52219-1
(2018) Methotrexate/nonsteroidal anti-inflammatories/omeprazole. Reactions Weekly, 1721 (1) 183 doi:10.1007/s40278-018-52220-0
(2018) Methotrexate/prednisone. Reactions Weekly, 1721 (1) 184 doi:10.1007/s40278-018-52221-0
(2018) Methylprednisolone. Reactions Weekly, 1721 (1) 185 doi:10.1007/s40278-018-52222-0
(2018) Methylprednisolone. Reactions Weekly, 1721 (1) 186 doi:10.1007/s40278-018-52223-0
(2018) Methylprednisolone/prednisone. Reactions Weekly, 1721 (1) 187 doi:10.1007/s40278-018-52224-0
(2018) Metoclopramide. Reactions Weekly, 1721 (1) 188 doi:10.1007/s40278-018-52225-0
(2018) Mixed amfetamine salts. Reactions Weekly, 1721 (1) 189 doi:10.1007/s40278-018-52226-0
(2018) Morphine. Reactions Weekly, 1721 (1) 190 doi:10.1007/s40278-018-52227-0
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 191 doi:10.1007/s40278-018-52228-0
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 192 doi:10.1007/s40278-018-52229-0
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 193 doi:10.1007/s40278-018-52230-z
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 194 doi:10.1007/s40278-018-52231-z
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 195 doi:10.1007/s40278-018-52232-z
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 196 doi:10.1007/s40278-018-52233-z
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 197 doi:10.1007/s40278-018-52234-z
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 198 doi:10.1007/s40278-018-52235-z
(2018) Multiple drugs. Reactions Weekly, 1721 (1) 199 doi:10.1007/s40278-018-52236-z
(2018) Multiple drugs overdose. Reactions Weekly, 1721 (1) 200 doi:10.1007/s40278-018-52237-z
(2018) Multiple drugs overdose. Reactions Weekly, 1721 (1) 201 doi:10.1007/s40278-018-52238-z
(2018) Multiple drugs overdose. Reactions Weekly, 1721 (1) 202 doi:10.1007/s40278-018-52239-z
(2018) Mycophenolate mofetil. Reactions Weekly, 1721 (1) 203 doi:10.1007/s40278-018-52240-y
(2018) Mycophenolate mofetil. Reactions Weekly, 1721 (1) 204 doi:10.1007/s40278-018-52241-y
(2018) Mycophenolate mofetil/prednisone/tacrolimus. Reactions Weekly, 1721 (1) 205 doi:10.1007/s40278-018-52242-y
(2018) Mycophenolate/prednisolone/tacrolimus. Reactions Weekly, 1721 (1) 206 doi:10.1007/s40278-018-52243-y
(2018) Nicorandil. Reactions Weekly, 1721 (1) 207 doi:10.1007/s40278-018-52244-y
(2018) Nimesulide. Reactions Weekly, 1721 (1) 208 doi:10.1007/s40278-018-52245-y
(2018) Nivolumab. Reactions Weekly, 1721 (1) 209 doi:10.1007/s40278-018-52246-y
(2018) Nivolumab. Reactions Weekly, 1721 (1) 210 doi:10.1007/s40278-018-52247-y
(2018) Nivolumab. Reactions Weekly, 1721 (1) 211 doi:10.1007/s40278-018-52248-y
(2018) Nivolumab. Reactions Weekly, 1721 (1) 212 doi:10.1007/s40278-018-52249-y
(2018) Nivolumab. Reactions Weekly, 1721 (1) 213 doi:10.1007/s40278-018-52250-x
(2018) Nivolumab. Reactions Weekly, 1721 (1) 214 doi:10.1007/s40278-018-52251-x
(2018) Nivolumab. Reactions Weekly, 1721 (1) 215 doi:10.1007/s40278-018-52252-x
(2018) Nivolumab. Reactions Weekly, 1721 (1) 216 doi:10.1007/s40278-018-52253-x
(2018) Nivolumab. Reactions Weekly, 1721 (1) 217 doi:10.1007/s40278-018-52254-x
(2018) Nivolumab. Reactions Weekly, 1721 (1) 218 doi:10.1007/s40278-018-52255-x
(2018) Nivolumab. Reactions Weekly, 1721 (1) 219 doi:10.1007/s40278-018-52256-x
(2018) Ofatumumab. Reactions Weekly, 1721 (1) 220 doi:10.1007/s40278-018-52257-x
(2018) Ofatumumab. Reactions Weekly, 1721 (1) 221 doi:10.1007/s40278-018-52258-x
(2018) Olanzapine. Reactions Weekly, 1721 (1) 222 doi:10.1007/s40278-018-52259-x
(2018) Olmesartan-medoxomil. Reactions Weekly, 1721 (1) 223 doi:10.1007/s40278-018-52260-9
(2018) Omalizumab. Reactions Weekly, 1721 (1) 224 doi:10.1007/s40278-018-52261-9
(2018) Omalizumab. Reactions Weekly, 1721 (1) 225 doi:10.1007/s40278-018-52262-9
(2018) Osimertinib. Reactions Weekly, 1721 (1) 226 doi:10.1007/s40278-018-52263-9
(2018) Osimertinib. Reactions Weekly, 1721 (1) 227 doi:10.1007/s40278-018-52264-9
(2018) Oxaliplatin. Reactions Weekly, 1721 (1) 228 doi:10.1007/s40278-018-52265-9
(2018) Oxycodone. Reactions Weekly, 1721 (1) 229 doi:10.1007/s40278-018-52266-9
(2018) Pazopanib. Reactions Weekly, 1721 (1) 230 doi:10.1007/s40278-018-52267-9
(2018) Pazopanib. Reactions Weekly, 1721 (1) 231 doi:10.1007/s40278-018-52268-9
(2018) PEG-3350/sodium-chloride/sodium-sulfate/potassium-chloride/ascorbic-acid. Reactions Weekly, 1721 (1) 232 doi:10.1007/s40278-018-52269-9
(2018) Peginterferon-α/ribavirin/sofosbuvir. Reactions Weekly, 1721 (1) 233 doi:10.1007/s40278-018-52270-8
(2018) Pembrolizumab. Reactions Weekly, 1721 (1) 234 doi:10.1007/s40278-018-52271-8
(2018) Pembrolizumab. Reactions Weekly, 1721 (1) 235 doi:10.1007/s40278-018-52272-8
(2018) Pembrolizumab. Reactions Weekly, 1721 (1) 236 doi:10.1007/s40278-018-52273-8
(2018) Pembrolizumab. Reactions Weekly, 1721 (1) 237 doi:10.1007/s40278-018-52274-8
(2018) Pembrolizumab. Reactions Weekly, 1721 (1) 238 doi:10.1007/s40278-018-52275-8
(2018) Penicillamine/trientine/zinc. Reactions Weekly, 1721 (1) 239 doi:10.1007/s40278-018-52276-8
(2018) Phentermine. Reactions Weekly, 1721 (1) 240 doi:10.1007/s40278-018-52277-8
(2018) Piperacillin/tazobactam/vancomycin. Reactions Weekly, 1721 (1) 241 doi:10.1007/s40278-018-52278-8
(2018) Pirfenidone. Reactions Weekly, 1721 (1) 242 doi:10.1007/s40278-018-52279-8
(2018) Ponatinib. Reactions Weekly, 1721 (1) 243 doi:10.1007/s40278-018-52280-7
(2018) Prednisone. Reactions Weekly, 1721 (1) 244 doi:10.1007/s40278-018-52281-7
(2018) Prednisone. Reactions Weekly, 1721 (1) 245 doi:10.1007/s40278-018-52282-7
(2018) Prednisone. Reactions Weekly, 1721 (1) 246 doi:10.1007/s40278-018-52283-7
(2018) Prednisone. Reactions Weekly, 1721 (1) 247 doi:10.1007/s40278-018-52284-7
(2018) Prednisone/sirolimus. Reactions Weekly, 1721 (1) 248 doi:10.1007/s40278-018-52285-7
(2018) Procaine. Reactions Weekly, 1721 (1) 249 doi:10.1007/s40278-018-52286-7
(2018) Propofol. Reactions Weekly, 1721 (1) 250 doi:10.1007/s40278-018-52287-7
1 2
Page 1 of 2		Next Page

See Also

These are possibly similar items as determined by title/reference text matching only.

(2018, September) Reactions Weekly Vol. 1717 (1) Springer Science and Business Media LLC
(2018, September) Reactions Weekly Vol. 1718 (1) Springer Science and Business Media LLC
(2018, September) Reactions Weekly Vol. 1719 (1) Springer Science and Business Media LLC
(2018, September) Reactions Weekly Vol. 1720 (1) Springer Science and Business Media LLC
(2016, September) Reactions Weekly Vol. 1617 (1) Springer Science and Business Media LLC
(2016, September) Reactions Weekly Vol. 1618 (1) Springer Science and Business Media LLC
(2016, September) Reactions Weekly Vol. 1619 (1) Springer Science and Business Media LLC
(2016, September) Reactions Weekly Vol. 1620 (1) Springer Science and Business Media LLC
(2007, September) Reactions Weekly Vol. 1167 (1) Springer Science and Business Media LLC
(2013, September) Reactions Weekly Vol. 1468 (1) Springer Science and Business Media LLC
(2013, September) Reactions Weekly Vol. 1469 (1) Springer Science and Business Media LLC
 
and/or  
Mindat.org is an outreach project of the Hudson Institute of Mineralogy, a 501(c)(3) not-for-profit organization.
Copyright © mindat.org and the Hudson Institute of Mineralogy 1993-2025, except where stated. Most political location boundaries are © OpenStreetMap contributors. Mindat.org relies on the contributions of thousands of members and supporters. Founded in 2000 by Jolyon Ralph.
To cite: Ralph, J., Von Bargen, D., Martynov, P., Zhang, J., Que, X., Prabhu, A., Morrison, S. M., Li, W., Chen, W., & Ma, X. (2025). Mindat.org: The open access mineralogy database to accelerate data-intensive geoscience research. American Mineralogist, 110(6), 833–844. doi:10.2138/am-2024-9486.
Privacy Policy - Terms & Conditions - Contact Us / DMCA issues - Report a bug/vulnerability Current server date and time: August 21, 2025 14:28:30
Go to top of page